Evidence map›Paper›PMID 31031981›Full record

ArticleMolecular and clinical oncology2019

Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.

Saudade André, Teresa Pereira, Fernanda Silva, Patrícia Machado, Fátima Vaz, Mariana Aparício, Giovani L Silva, António E Pinto

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Saudade AndréDepartment of Pathology, Portuguese Institute of Oncology of Lisbon, 1099-023 Lisbon, Portugal.
Teresa PereiraDepartment of Pathology, Portuguese Institute of Oncology of Lisbon, 1099-023 Lisbon, Portugal.
Fernanda SilvaNOVA Medical School, NOVA University, 1169-056 Lisbon, Portugal.
Patrícia MachadoBreast Cancer Risk Evaluation Clinic, Portuguese Institute of Oncology of Lisbon, 1099-023 Lisbon, Portugal.
Fátima VazBreast Cancer Risk Evaluation Clinic, Portuguese Institute of Oncology of Lisbon, 1099-023 Lisbon, Portugal.
Mariana AparícioDepartment of Mathematics of Higher Technical Institute, University of Lisbon, Portugal.
Giovani L SilvaDepartment of Mathematics of Higher Technical Institute, University of Lisbon, Portugal.
António E PintoDepartment of Pathology, Portuguese Institute of Oncology of Lisbon, 1099-023 Lisbon, Portugal.
Instituto Português de Oncologia Francisco Gentil · PTUniversity of Lisbon · PTUniversidade Nova de Lisboa · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Male breast cancer (BC) represents an individual subtype of BC, with therapeutic procedures based on female BC therapy results. The present study evaluated the parameters currently used for the characterization and therapy of male BC, and their association with disease-free (DFS) and overall survival (OS), aiming to obtain a comprehensive basis to improve the personalized care of male BC. A total of 196 patients from March 1970 to March 2018 (mean follow-up, 84.9 months) were profiled, using clinicopathological review, molecular assessment [BRCA1/2, DNA repair associated (BRCA1/2) status, immunohistochemistry, fluorescence

Indexed as

clinicopathological characteristicsmale breast cancermolecular featuressurvival

Identifiers

PMID31031981
PMCPMC6482395
OpenAlexW2937541629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.